2024
Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.
Zeidan A, Santini V, Platzbecker U, Sekeres M, Savona M, Fenaux P, Madanat Y, Raza A, Xia Q, Sun L, Riggs J, Shah S, Navada S, Berry T, Komrokji R. Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge. Journal Of Clinical Oncology 2024, 42: 6566-6566. DOI: 10.1200/jco.2024.42.16_suppl.6566.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesRBC-TIMyeloid growth factorsPlatelet transfusionsTransfusion-dependentHb levelsGrowth factorGrowth factor supportLong-term respondersGrowth factor useErythropoiesis stimulating agentsHb riseSevere neutropeniaMyelodysplastic syndromePlacebo groupPrimary endpointSecondary endpointsFactor supportInvestigator's discretionClinical benefitAdverse eventsPlaceboAnalysis cutoffImetelstatDisease progression
2016
Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database
Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA. Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer 2016, 122: 1209-1215. PMID: 26914833, DOI: 10.1002/cncr.29913.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overCause of DeathCritical IllnessDatabases, FactualFemaleHospice CareHumansIntensive Care UnitsLogistic ModelsMaleMultivariate AnalysisMyelodysplastic SyndromesOdds RatioPatient Care TeamQuality of Health CareRetrospective StudiesRisk AssessmentSEER ProgramSex FactorsSurvival AnalysisTerminal CareUnited StatesConceptsMyelodysplastic syndromeDays of lifeHospice enrollmentLife careEnd Results-Medicare databaseIntensive care unit admissionEOL quality measuresIntensity of endIntensity of EOLCare unit admissionTransfusion-dependent patientsLarge national databaseUnit admissionPalliative needsNonwhite patientsRed blood cellsMDS patientsPlatelet transfusionsHospice useEOL careHospice modelMultivariable modelLower oddsPatientsPopulation ages
2015
North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
Pine A, Lee E, Sekeres M, Steensma D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba H, Garcia-Manero G, Lee A, Podoltsev N, Barbarotta L, Hendrickson J, Gore S, Zeidan A. North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood 2015, 126: 1138. DOI: 10.1182/blood.v126.23.1138.1138.Peer-Reviewed Original ResearchRed blood cell transfusionNon-bleeding patientsBlood cell transfusionBone marrow biopsyBlood product transfusionSouthwest Oncology GroupPlatelet transfusionsOutpatient settingAcute leukemiaPlatelet levelsCell transfusionHemoglobin levelsTransfusion practiceLumbar punctureFibrinogen levelsProduct transfusionHospitalized patientsOncology GroupClinical trialsPlatelet thresholdMost respondersConsensus evidence-based guidelinesMost providersEastern Cooperative Oncology GroupStable hospitalized patients
2014
An update on type 2B von Willebrand disease
Mikhail S, Aldin ES, Streiff M, Zeidan A. An update on type 2B von Willebrand disease. Expert Review Of Hematology 2014, 7: 217-231. PMID: 24521271, DOI: 10.1586/17474086.2014.868771.Peer-Reviewed Original ResearchConceptsVon Willebrand diseaseType 2B von Willebrand diseaseVon Willebrand factorAbnormal von Willebrand factorWillebrand diseaseHigh molecular weight VWF multimersSignificant clinical variationWeight VWF multimersPlatelet countPlatelet transfusionsReplacement therapyPlatelet clearanceVWD patientsTransient decreaseClinical variationFactor VIIIWillebrand factorDiseaseVWF multimersPatientsIdentical mutationsSuboptimal resultsTransfusionDesmopressinPreferential loss